SEC Form 4 · accession 0001209191-15-024608

Vanda Pharmaceuticals Inc. · VNDA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 9, 2015

Accepted (ET)

Mar 10, 2015 · 4:32 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001347178

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 9, 2015	M	10,574	$4.7329	A	10,574	D
Common Stock^F1	Mar 9, 2015	S	4,804	$10.6859	D	5,770	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Nonqualified Stock Option (Right to Buy)^F3,F2,F4	$4.73	Mar 9, 2015	M	10,574	D	—	Dec 29, 2015	Common Stock	10,574	0	D

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.66 to $10.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
F2Reflects the converted exercise price of each option share pursuant to the 1-for-3.309755 reverse stock split which occurred immediately following the effectiveness of the registration statement covering the issuer's initial public offering.
F3The Form 3 originally filed on April 12, 2006 inadvertently listed 10,571 shares of Common Stock instead of 10,574 shares of Common Stock.
F4Exercisable with respect to 660 shares immediately. Exercisable with respect to an additional 2.08333% of the aggregate option share total each month thereafter.